The US Centers for Medicare and Medicaid Services (CMS) has proposed to not issue a National Coverage Determination (NCD) for AlloMap molecular testing to detect rejection of cardiac allografts, leaving any coverage decisions on use of the diagnostics up to local Medicare contractors instead.
Due to the very low number of tests – which are performed on fewer than 1% of Medicare beneficiaries – and the need for careful patient selection, the CMS believes...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?